Get the Stockscreener App
28.50
2.78%
0.77
After Hours:
28.50
Agios Pharmaceuticals Inc stock is traded at $28.50, with a volume of 678.36K.
It is up +2.78% in the last 24 hours and up +5.28% over the past month.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
See More
Previous Close:
$27.73
Open:
$27.78
24h Volume:
678.36K
Relative Volume:
0.66
Market Cap:
$1.69B
Revenue:
$66.05M
Net Income/Loss:
$-422.60M
P/E Ratio:
-3.9305
EPS:
-7.251
Net Cash Flow:
$-384.73M
1W Performance:
-0.94%
1M Performance:
+5.28%
6M Performance:
+16.00%
1Y Performance:
-5.54%
1-Day Range:
$27.64
$28.85
1-Week Range:
$27.45
$29.18
52-Week Range:
$22.24
$46.00
Agios Pharmaceuticals Inc Stock (AGIO) Company Profile
Name
Agios Pharmaceuticals Inc
Sector
Industry
Phone
617-649-8600
Address
88 SIDNEY STREET, CAMBRIDGE, MA
Compare AGIO vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AGIO
Agios Pharmaceuticals Inc
|
28.50 | 1.68B | 66.05M | -422.60M | -384.73M | -7.251 |
VRTX
Vertex Pharmaceuticals Inc
|
430.44 | 110.81B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.76 | 66.02B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
804.25 | 48.27B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.48 | 38.22B | 4.29B | 577.22M | 641.34M | 4.2086 |
ONC
Beone Medicines Ltd Adr
|
308.74 | 30.41B | 5.76B | 514.49M | 1.10B | 4.4813 |
Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-20-26 | Reiterated | H.C. Wainwright | Buy |
| Nov-24-25 | Initiated | Truist | Buy |
| Nov-20-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-19-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-24-25 | Initiated | H.C. Wainwright | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Sep-27-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Feb-08-24 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-03-23 | Initiated | Piper Sandler | Overweight |
| Nov-17-22 | Upgrade | Goldman | Sell → Neutral |
| Jul-27-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Dec-03-21 | Initiated | BofA Securities | Buy |
| Jul-30-21 | Downgrade | Goldman | Neutral → Sell |
| Jul-01-21 | Initiated | Raymond James | Mkt Perform |
| Jun-10-21 | Initiated | H.C. Wainwright | Buy |
| Mar-01-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Mar-01-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Feb-26-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Oct-22-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Mar-04-20 | Initiated | Barclays | Equal Weight |
| Nov-26-19 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-23-19 | Upgrade | Guggenheim | Neutral → Buy |
| May-23-19 | Resumed | Goldman | Neutral |
| Feb-15-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-25-18 | Initiated | Leerink Partners | Mkt Perform |
| May-23-18 | Initiated | Citigroup | Buy |
| Apr-11-18 | Reiterated | Credit Suisse | Outperform |
| Feb-15-18 | Reiterated | Needham | Buy |
| Feb-15-18 | Reiterated | SunTrust | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Aug-10-17 | Reiterated | Needham | Buy |
| Aug-08-17 | Reiterated | SunTrust | Buy |
| Aug-02-17 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
| Jun-26-17 | Downgrade | Janney | Buy → Neutral |
| Jan-17-17 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-24-16 | Initiated | Needham | Buy |
| Jun-13-16 | Upgrade | JP Morgan | Neutral → Overweight |
| May-18-16 | Reiterated | SunTrust | Buy |
View All
Agios Pharmaceuticals Inc Stock (AGIO) Latest News
Agios Pharmaceuticals Touts Strong AQVESME Launch as Sickle Cell Filing Advances - Yahoo Finance
Agios Pharmaceuticals Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
AGIO beats on Q1 earnings & sales, stock up 13% on new drug momentum - MSN
Why is Agios Pharmaceuticals stock surging Tuesday afternoon? - MSN
Agios plans Q2 sNDA filing for mitapivat in sickle cell disease while citing >$10B 2030 market opportunity - MSN
How Investors Are Reacting To Agios Pharmaceuticals (AGIO) FDA Bid For Mitapivat In Sickle Cell Disease - Sahm
Armistice Capital (NASDAQ: AGIO) holds 2.716M shares, 4.57% stake - Stock Titan
Assessing Agios Pharmaceuticals (AGIO) Valuation After Recent Share Price Volatility - Yahoo Finance
How Agios’ Mitapivat sNDA And New SCD Trial Design At Agios Pharmaceuticals (AGIO) Has Changed Its Investment Story - Yahoo Finance
Developer seeking FDA’s accelerated approval for mitapivat for SCD - Sickle Cell Disease News
TradingKey - TradingKey
Agios sNDA And EHA Plenary Put Mitapivat At Center Of Valuation - Yahoo Finance
Agios Seeks FDA Nod to Expand Mitapivat Label in Sickle Cell Disease - The Globe and Mail
Agios Pharmaceuticals (AGIO) Showcases Promising Mitapivat Data at EHA 2026 - GuruFocus
Agios submits application for mitapivat in sickle cell disease - Investing.com UK
Agios presents mitapivat data at European hematology congress By Investing.com - Investing.com Australia
Agios submits application for mitapivat in sickle cell disease By Investing.com - Investing.com Australia
Agios presents mitapivat data at European hematology congress - Investing.com
Agios Pharmaceuticals to Present RISE UP Phase 3 Trial Results of Mitapivat in Sickle Cell Disease at EHA 2026 Plenary Session - Quiver Quantitative
Agios Submits sNDA to FDA for U.S. Accelerated Approval of Mitapivat in Sickle Cell Disease - The Manila Times
Agios to Present New Data at EHA 2026 Reinforcing the Significant Therapeutic Impact of Mitapivat Across Multiple Rare Hemolytic Anemias - The Manila Times
New pill for sickle cell moves to FDA review, aims to cut transfusions - Stock Titan
Oral drug lifts hemoglobin in sickle cell and thalassemia trial - Stock Titan
Price-Driven Insight from (AGIO) for Rule-Based Strategy - Stock Traders Daily
47,414 Shares in Agios Pharmaceuticals, Inc. $AGIO Acquired by State of New Jersey Common Pension Fund D - MarketBeat
Number of shareholders of Agios Pharmaceuticals, Inc. – TRADEGATE:8AP - TradingView
Lynx1 (AGIO) discloses 5.1% stake — 3.01M shares reported - Stock Titan
Need To Know: Analysts Are Much More Bullish On Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Revenues - 富途牛牛
Agios Pharmaceuticals, Inc. $AGIO Shares Sold by Pictet Asset Management Holding SA - MarketBeat
Agios Pharmaceuticals Stock Rises 11.2% on Strong Q1 2026 Aqvesme Launch and Pipeline Progress - IndexBox
Agios Pharmaceuticals (AGIO) Is Up 11.2% After Rare Disease Launch And FDA Acceleration NewsHas The Bull Case Changed? - Sahm
Here's Why Shares in Agios Pharmaceuticals Soared This Week (And What to Expect Next in 2026) - Yahoo Finance
RBC Capital Sticks to Its Hold Rating for Agios Pharma (AGIO) - The Globe and Mail
MSN Money - MSN
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q1 2026 Earnings Call Transcript - Insider Monkey
Agios Pharmaceuticals Hits Day High with 13.1% Surge in Stock Price - Markets Mojo
Agios Pharmaceuticals Reports 20.7 Million Dollars in Q1 Revenue - HarianBasis.co
AGIO Beats on Q1 Earnings & Sales, Stock Up 13% on New Drug Momentum - The Globe and Mail
Agios (AGIO) Q1 2026 Earnings Call Transcript - AOL.com
AGIO Maintained by Truist Securities -- Price Target Lowered to $36 - GuruFocus
Why Agios Pharmaceuticals Stock Zoomed to a 13% Gain on Wednesday - AOL.com
Truist Financial Issues Pessimistic Forecast for Agios Pharmaceuticals (NASDAQ:AGIO) Stock Price - MarketBeat
Agios Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
(AGIO) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Agios Pharmaceuticals Inc (AGIO) Q1 2026 Earnings Call Highlights: Robust Revenue Growth and Strategic Advances - GuruFocus
Agios Pharmaceuticals Inc Stock (AGIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Agios Pharmaceuticals Inc Stock (AGIO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Burns James William | Chief Legal Officer |
Apr 02 '26 |
Sale |
34.71 |
3,280 |
113,849 |
49,306 |
| Gheuens Sarah | Chief Medical Officer |
Apr 02 '26 |
Option Exercise |
0.00 |
8,500 |
0 |
83,217 |
| Gheuens Sarah | Chief Medical Officer |
Apr 02 '26 |
Sale |
34.71 |
2,940 |
102,047 |
80,277 |
| Jones Cecilia | Chief Financial Officer |
Apr 02 '26 |
Option Exercise |
0.00 |
8,500 |
0 |
58,139 |
| Jones Cecilia | Chief Financial Officer |
Apr 02 '26 |
Sale |
34.71 |
3,141 |
109,024 |
54,998 |
| Milanova Tsveta | Chief Commercial Officer |
Apr 02 '26 |
Option Exercise |
0.00 |
8,500 |
0 |
50,091 |
| Milanova Tsveta | Chief Commercial Officer |
Apr 02 '26 |
Sale |
34.71 |
3,262 |
113,224 |
46,829 |
| Viswanadhan Krishnan | Chief Corp Dev & Strategy |
Apr 02 '26 |
Option Exercise |
0.00 |
8,100 |
0 |
13,241 |
| Viswanadhan Krishnan | Chief Corp Dev & Strategy |
Apr 02 '26 |
Sale |
34.71 |
2,959 |
102,707 |
10,282 |
| Goff Brian | Chief Executive Officer |
Apr 02 '26 |
Option Exercise |
0.00 |
39,028 |
0 |
191,104 |
2.93%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):